OncoMed Pharmaceuticals has begun a Phase Ib/II study to assess the efficacy of its anti-cancer stem cell candidate OMP-21M18, or demcizumab, with paclitaxel against platinum-resistant ovarian cancer, primary peritoneal cancer and fallopian tube cancer. The drug is also in early stage trials against pancreatic cancer and nonsmall-cell lung cancer.

Full Story:
RTT News

Related Summaries